Healthcare
Live Price
Offline$15.30
-0.65% today
1Y Change
-12.91%
Window
Jun 23, 2025 → Jun 9, 2026
Coverage: 242 bars · Jun 23, 2025 → Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tandem Diabetes Care, Inc. (TNDM) is a Healthcare stock with a market cap of $1.33B and listed on NASDAQ. The stock last traded around $15.30 and down 12.9% across the available one-year price window (Jun 23, 2025 → Jun 9, 2026). Baseline metrics include revenue growth of +7.9%, EPS growth of -106.8%, a dividend yield of 0.0%. What stands out right now is revenue +7.9%, EPS -106.8%, free cash flow -694.1% with operating margin -18.2% and ROIC -27.8%. Valuation is more restrained than many high-expectation growth names at price/sales 1.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TNDM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TNDM
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TNDM Max Drawdown
-54.64%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TNDM and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$702.8M
-12.3% YoY
FY Net Income
$15.6M
+116.5% YoY
Free Cash Flow
$87.8M
+436.7% YoY
Revenue Growth
+7.9%
EPS Growth
-106.8%
Gross Margin
53.8%
Net Margin
-20.2%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.0B | 940M | 748M | 801M | 703M |
| Gross Profit | 531M | 490M | 368M | 413M | 376M |
| Operating Income | -78M | -99M | -233M | -93M | 23M |
| EBITDA | -175M | -99M | -196M | -74M | 34M |
| Net Income | -205M | -96M | -223M | -95M | 16M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 91M | 69M | 59M | 173M | 71M |
| Total Assets | 881M | 968M | 953M | 1.1B | 905M |
| Total Liabilities | 726M | 705M | 639M | 613M | 472M |
| Shareholder Equity | 155M | 263M | 314M | 440M | 433M |
| Total Debt | 444M | 474M | 416M | 420M | 315M |
| Net Debt | 354M | 404M | 357M | 247M | 243M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
111M
+120.7% YoY
Capital Expenditures
24M
+31.0% YoY
Free Cash Flow
88M
+436.7% YoY
Key ratios
Gross Margin
53.8%
Operating Margin
-18.2%
Net Margin
-20.2%
ROE
-142.0%
Debt / Equity
3.64x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.